To this end, targeting of CCR2+ macrophages using CCR2 inhibitors is an effective method of tumor control in mouse models of PDA and has shown safety and potential clinical activity in combination with FOLFIRINOX in patients (40, 56). Here, CCR2 is linked to neoplasm.